title: Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study.
abstract: This study sought to investigate the cardiac and renal effects of rigorous versus standard BP control on autosomal-dominant polycystic kidney disease (ADPKD). A prospective, randomized, 7-yr study was performed to examine the effect of rigorous (<120/80 mmHg) versus standard (135-140/85-90 mmHg) BP control on left ventricular mass index (LVMI) and kidney function in 75 hypertensive ADPKD patients with left ventricular hypertrophy. LVMI was measured by echocardiogram at baseline and at 1 and 7 yr. Renal function was assessed by measuring serum creatinine and 24-h creatinine clearance every 6 mo for 3 yr, then annually for an additional 4 yr. The baseline characteristics were comparable in the two groups. During the study, average mean arterial pressure was 90 +/- 5 mmHg for the rigorous group and 101 +/- 4 mmHg for the standard group (P < 0.0001). The LVMI decreased by 21% in the standard group and by 35% in the rigorous group. A mixed model longitudinal data analysis revealed that rigorous BP control was significantly more effective in decreasing LVMI (P < 0.01). There was no statistically significant difference in renal function between the two groups. In conclusion, left ventricular hypertrophy, a major cardiovascular risk factor, was decreased to a significantly greater extent by rigorous than standard BP control. This finding has particular clinical importance because cardiovascular complications are the most common cause of death in ADPKD patients.
authors.affiliation: Department of Medicine, Health Sciences Center, University of Colorado School of Medicine, 4200 East Ninth Avenue, Denver, CO 80262, USA. Robert.Schrier@uchsc.edu
authors.forename: Robert
authors.initials: R
authors.lastname: Schrier
authors.forename: Kimberly
authors.initials: K
authors.lastname: McFann
authors.forename: Ann
authors.initials: A
authors.lastname: Johnson
authors.forename: Arlene
authors.initials: A
authors.lastname: Chapman
authors.forename: Charles
authors.initials: C
authors.lastname: Edelstein
authors.forename: Godela
authors.initials: G
authors.lastname: Brosnahan
authors.forename: Tevfik
authors.initials: T
authors.lastname: Ecder
authors.forename: Lyn
authors.initials: L
authors.lastname: Tison
mesh_terms: D000328:Adult; D017311:Amlodipine / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure; D003404:Creatinine / Q000097:blood; D004452:Echocardiography; D004656:Enalapril / Q000627:therapeutic use*; D005260:Female; D006321:Heart / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology*; D017379:Hypertrophy, Left Ventricular / Q000000981:diagnostic imaging / Q000209:etiology; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D016891:Polycystic Kidney, Autosomal Dominant / Q000150:complications* / Q000503:physiopathology; D011446:Prospective Studies
chemical_list: D000959:Antihypertensive Agents; D017311:Amlodipine; D004656:Enalapril; D003404:Creatinine